| Overview |
| bs-21629R-Cy3 |
| MAP3K8 Polyclonal Antibody, Cy3 Conjugated |
| WB |
| Human, Mouse, Rat |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MAP3K8 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| P41279 |
| 1326 |
| c COT; Cancer Osaka thyroid oncogene; Cancer Osaka thyroid oncogene; CCOT; COT; COT proto oncogene serine/threonine protein kinase; EST; ESTF; Ewing sarcoma transformant; FLJ10486; M3K8_HUMAN; MAP3K 8; MAP3K8; Mitogen activated protein kinase kinase kinase 8; Mitogen-activated protein kinase kinase kinase 8; Proto oncogene cCot; Proto-oncogene c-Cot; Serine/threonine protein kinase cot; Serine/threonine-protein kinase cot; TPL 2; TPL-2; TPL2; Tumor progression locus 2. |
| This gene is an oncogene that encodes a member of the serine/threonine protein kinase family. The encoded protein localizes to the cytoplasm and can activate both the MAP kinase and JNK kinase pathways. This protein was shown to activate IkappaB kinases, and thus induce the nuclear production of NF-kappaB. This protein was also found to promote the production of TNF-alpha and IL-2 during T lymphocyte activation. This gene may also utilize a downstream in-frame translation start codon, and thus produce an isoform containing a shorter N-terminus. The shorter isoform has been shown to display weaker transforming activity. Alternate splicing results in multiple transcript variants that encode the same protein. [provided by RefSeq, Sep 2011] |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz